Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00312 |
| Species: | Homo sapiens |
| Position : | chr8:41184163-41184463 |
| Year: | 2023 |
| Title: | SOX17 enhancer variants disrupt transcription factor binding and enhancer inactivity drives pulmonary hypertension |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | pancreatic ductal adenocarcinoma |
| PMID: | 37066790 |
| MONDO: | MONDO:0005147 |
| Tissue: | Pancreas |
| Tissue Ontology ID: | UBERON:0001264 |
| Cell Source: | PacR |
| CVCL ID: | |
| Cell Type: | pancreatic ductal adenocarcinoma cell |
| Cell Ontology ID: | CL:0000066 |
| Experiment Type: | Enhancer activity assay, Functional perturbation assay |
| High Throughput Method: | ChIP-seq, RNA-seq |
| Low Throughput Method: | Luciferase Reporter Assay, CRISPRi, CRISPR Knockout, EMSA, ChIP-RT-qPCR |
| Target gene : | SOX17 |
| TF name : | HOXA5 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|